Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...
Hosted on MSN5h
Canaccord Genuity Upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...
CRISPR stock rating raised to hold by TD Cowen, target steady
CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Wall Street Fear Gauge Edges Up Ahead of Inflation Data
Investors were feeling zen on Wednesday, with no major news about Donald Trump's tariffs to worry about ahead of the monthly ...
Cracking the Alzheimer's code: How brain trauma triggers a hallmark of the disease
A study at Lund University reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta—a hallmark of Alzheimer's disease. The findings ...